Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080650 · ClinicalTrials.gov registry record · NA
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 62
- Enrollment target
NCT02080650 is a NA study that has completed, run by Duke University. The registered enrollment target is 62 participants.
The verdict
NCT02080650, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
Study Summary
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid. The primary objective of this pilot study will be to describe the numbers of c-MET expressing cells that can be detected by the c-MET CTC capture technique. These data will be separated by disease site. The investigator will also describe the detection rates of both the c-MET CTC capture and the EpCAM CTC capture techniques in each patient, also separated by disease site.
Interventions
- DEVICE Mesenchymal-marker based ferrofluid (c-MET)
- DEVICE Epithelial cell adhesion molecule (EpCAM) ferrofluid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-07-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02080650
The ClinicalTrials.gov registry entry for NCT02080650 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mesenchymal-marker based ferrofluid (c-MET) is the first listed.
NCT02080650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02080650 about?
NCT02080650 is a clinical study titled "Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)". This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid. The primary objective of this pilot study will be to describe the numbers of c-MET expressing cells that can be detected by the c-MET CTC capture technique. These data...
What is the current status of trial NCT02080650?
This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2014-03. Estimated completion is 2016-07-19.
What interventions are being tested in trial NCT02080650?
The interventions under investigation include: Mesenchymal-marker based ferrofluid (c-MET) (DEVICE), Epithelial cell adhesion molecule (EpCAM) ferrofluid (DEVICE).
Who is sponsoring clinical trial NCT02080650?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.